Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Tarloxotinib treatment leads to tumor regression
May 2019
SHARING OPTIONS:

NEWARK, Calif.—The recent 2019 AACR annual meeting saw Rain Therapeutics Inc. present new preclinical data on tarloxotinib (Tarlox). Among the findings were data showing that Tarlox led to tumor growth inhibition and tumor regression in an NRG1 ovarian cancer patient-derived xenograft model, and a 100-percent reduction in tumor size in the group dosed with Tarlox vs. a 150-percent increase in size in the control group. Tarlox was also found to inhibit proliferation of EGFR and HER2 Exon 20 insertion mutations and osimertinib-resistant mutations in vitro.
“Taken together, these exciting results provide strong evidence for the broad potential of Tarlox as a targeted cancer therapy,” said CEO Avanish Vellanki. “These data are encouraging as we continue our Phase 2 clinical trial of Tarlox in non-small cell lung cancer with EGFR exon 20 insertion and HER2 activating mutations, and we are looking forward to continuing to advance Tarlox through clinical development.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.